Yashoda Super Specialty Kaushambi
The Subject Expert Committee of Drugs Controller General of India (DCGI) on Wednesday recommended Serum Institute’s indigenously developed quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients.
“An expert panel of India’s central drug authority on Wednesday recommended granting of market authorisation to Serum Institute of India (SII) indigenously-developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer”, said a source.
The vaccine has been recommended for cervical cancer patients those above 9 years to 26 years of age for both male and female.According to the source, an application has also been sent to the National Technical Advisory Group on Immunisation (NTAGI).
The NTAGI may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.
Under the Yellow Ribbon Campaign conceptualized in 1998 by Dr S K Sarin with the…
In a written reply to a question in the Rajya Sabha, Union Health Minister J…
India achieved 48.7 per cent decline in annual new HIV infections and 81.4 per cent reduction in AIDS-related…
In a significant medical achievement, doctors at HCMCT Manipal Hospital Dwarka, New Delhi, successfully performed…
Preventive health checks play a crucial role in identifying pollution-related risks early, especially for smokers,…
The Winter Session of Parliament has begun from Monday with a packed legislative agenda, including…